Internal Medicine, Rheumatology · Lynn Haven, FL
NPI
1770780603
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3890 Jenks Ave
Lynn Haven, FL, 32444
Phone (850) 215-6400
Groups this clinician bills Medicare through
Medicare paid, 2024
$6.0M
335,165 services
Medicare patients, 2024
1,631
Average age 73
Drug cost, 2024
$2.9M
1,852 prescriptions
Company payments, 2025
$3,722
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Aymen A Kenawy was code J1602 (injection, golimumab, 1 mg, for intravenous use), 69,563 times for 102 patients. In total Aymen A Kenawy billed 335,165 services in 133 codes, and Medicare paid $6.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-07-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 69,563 | 102 | $8.91 | $620K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 65,496 | 113 | $33.47 | $2.2M |
| J3262 Injection, tocilizumab, 1 mg | Office | 54,998 | 15 | $4.43 | $244K |
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 25,401 | 14 | $3.63 | $92K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 16,171 | 23 | $8.54 | $138K |
| J0897 Injection, denosumab, 1 mg | Office | 13,561 | 167 | $20.17 | $274K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 6,865 | 491 | $0.08 | $583 |
| 95004 Test - Miscellaneous | Office | 6,696 | 91 | $3.02 | $20K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 6,420 | 27 | $24.41 | $157K |
| J9312 Injection, rituximab, 10 mg | Office | 4,250 | 17 | $61.34 | $261K |
| J7318 Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | Office | 3,420 | 37 | $5.03 | $17K |
| 99214 Office E&M - Established | Office | 3,038 | 1,267 | $95.30 | $290K |
| 86235 Immunoassay | Office | 3,035 | 376 | $17.52 | $53K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 2,140 | 1,079 | $13.38 | $29K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 2,079 | 61 | $0.23 | $469 |
By year: 2022 $6.9M for 360,291 services; 2023 $6.1M for 353,919 services; 2024 $6.0M for 335,165 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 86235 Immunoassay | 3,035 | 376 | $17.52 | $53K |
| 83516 Immunoassay | 1,597 | 780 | $11.27 | $18K |
| 82306 Clinical Chemistry | 947 | 856 | $28.95 | $27K |
| 86146 Immunoassay | 946 | 314 | $24.86 | $24K |
| 86800 Immunoassay | 849 | 825 | $15.55 | $13K |
| 86376 Immunoassay | 849 | 826 | $14.23 | $12K |
| 86200 Immunoassay | 809 | 788 | $12.66 | $10K |
| 86431 Immunoassay | 797 | 778 | $5.55 | $4,420 |
| 86225 Immunoassay | 384 | 378 | $13.43 | $5,159 |
| 86226 Immunoassay | 382 | 376 | $11.84 | $4,522 |
Medicare prescription drug claims, 2024
In 2024, the drug Aymen A Kenawy prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 492 prescriptions and refills. In total Aymen A Kenawy wrote 1,852 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 492 | 1,040 | 228 | $19K |
| Ibandronate Sodium Generic | 173 | 474 | 83 | $4,184 |
| Methotrexate Methotrexate Sodium | 132 | 295 | 69 | $3,267 |
| Orencia Abatacept/Maltose | 129 | 129 | 17 | $659K |
| Prednisone Generic | 61 | 141 | 30 | $393 |
| Meloxicam Generic | 55 | 122 | 34 | $339 |
| Tramadol Hcl Generic | 52 | 52 | 23 | $609 |
| Celecoxib Generic | 51 | 109 | 23 | $1,088 |
| Simponi Aria Golimumab | 49 | 58 | Under 11 | $396K |
| Allopurinol Generic | 47 | 128 | 21 | $699 |
| Humira(Cf) Pen Adalimumab | 44 | 44 | 11 | $446K |
| Duloxetine Hcl Generic | 38 | 80 | 20 | $715 |
| Gabapentin Generic | 38 | 89 | 14 | $708 |
| Leflunomide Generic | 34 | 76 | 20 | $2,235 |
| Folic Acid Generic | 27 | 34 | Under 11 | $96.14 |
Brand drugs: - claims; generic drugs: 1,428 claims; opioid claims: 57.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Aymen A Kenawy $3,722 ($3,722 in general payments such as food, travel and fees) from 23 companies. The largest payer was Amgen Inc. with $847.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 38 | $847 |
| UCB, Inc. UCB.BR | 18 | $591 |
| Abbvie Inc. ABBV | 23 | $514 |
| Novartis Pharmaceuticals Corporation NVS | 15 | $283 |
| GlaxoSmithKline, LLC. GSK | 6 | $214 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $195 |
| ANI Pharmaceuticals, Inc. ANIP | 4 | $164 |
| Genzyme Corporation SNY | 6 | $134 |
| Ferring Pharmaceuticals Inc. | 5 | $115 |
| Mallinckrodt Hospital Products Inc. | 4 | $86.69 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.